VJHemOnc is committed to improving our service to you

EHA 2019 | Waldenström’s: predicting ibrutinib responses

VJHemOnc is committed to improving our service to you

Steven Treon

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses data presented at EHA 2019 that investigated predictive factors for long-term response in waldenström’s macroglobulinemia treated with ibrutinib at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter